Entera Bio Ltd. (ENTX)

Entera Bio Ltd. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Entera Bio Ltd. (ENTX) is a Biotechnology company based in IL with a market capitalization of $62.3M. Free cash flow was negative at -$7.5M. This page tracks ENTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

IL · 18 employees · IPO Jun 28, 2018

Valuation

Valuation & price

$1.21as of May 26, 2026· -61.5% vs 52w high

P/E ratio

Latest-FY diluted EPS

4.75

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$3.11$2.10$1.09Jul 25Dec 25Jul 26
$1.0052-week range$3.14
Loading valuation history…

Fundamentals

Key fundamentals

$62.3M

Market cap

Revenue growth (YoY)

0.0%

Gross margin

-$7.5M

Free cash flow (USD)

-$6.6M

Net debt

Net cash position

22.7%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$0$42K

Free cash flow by year

20162025

-$3.2M-$7.5M

Gross margin by year

20212025

34.7%0.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 8, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventMay 8, 2026Filing

    Earnings Release

  • Quarterly reportMay 8, 2026Filing

    10-Q Filed

  • FinancingMay 8, 2026Filing

    Securities Registration

  • 8-K eventApr 3, 2026Filing

    Securities Purchase Agreement

Questions

Frequently asked questions

What is Entera Bio Ltd.'s market cap?

Entera Bio Ltd. (ENTX) has a market capitalization of $62.3M.

What is ENTX's P/E ratio?

A meaningful P/E ratio is not available for ENTX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is ENTX's price-to-book (P/B) ratio?

ENTX trades at 4.75 times book value per share.

Are insiders buying ENTX stock?

SEC Form 4 filings show no open-market insider buys at Entera Bio Ltd. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.